A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants
Phase of Trial: Phase I
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Daratumumab/hyaluronidase (Primary)
- Indications Amyloid light-chain amyloidosis; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-small cell lung cancer; Prostate cancer; Solid tumours; T-cell lymphoma
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 04 Sep 2019 Status changed from active, no longer recruiting to completed.
- 20 Jun 2019 Planned End Date changed from 17 Jun 2019 to 27 Aug 2019.
- 20 Jun 2019 Planned primary completion date changed from 3 Jun 2019 to 27 Aug 2019.